BioSpace News Archive

City of Hope announced that data from an investigational Phase 1/2, single arm trial using a bispecific antibody called mosunetuzumab highlights the paradigm-changing potential of a new treatment option for people with follicular lymphoma, a type of blood cancer and the most common indolent form of non-Hodgkin lymphoma.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with immune system dysfunction, announced new positive efficacy and safety data from the ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, for patients with Waldenström’s macroglobulinemia and confirmed MYD88 and CXCR4 mutations.

Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, released a summary of ALETA-001 preclinical results from a poster being presented at the 63rd American Society of Hematology Annual Meeting, held in Atlanta, Georgia and in a virtual platform on December 11-14, 2021.

Kite, a Gilead Company, announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® in adult patients with refractory large B-cell lymphoma.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® plus venetoclax as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new analyses illustrating responses that first-line treatment with DARZALEX® -based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone.

Three studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition throw a spotlight on novel approaches to screening for and treating blood diseases, as well as an unexpected, potential association between a blood abnormality and Alzheimer’s disease.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced updated positive data from its Phase 1/2 trial of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease despite two or more prior lines of therapy.